Stephen Chia

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. doi request reprint Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT
    Stephen Chia
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10 Avenue, Vancouver, BC, Canada
    J Clin Oncol 26:1664-70. 2008
  2. doi request reprint Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer
    Stephen Chia
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada
    Breast 17:S16-21. 2008
  3. pmc A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen
    Stephen K Chia
    Department of Medical Oncology, British Columbia Cancer Agency, British Columbia, Canada
    Clin Cancer Res 18:4465-72. 2012
  4. ncbi request reprint Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial
    Stephen Chia
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada
    J Clin Oncol 24:2773-8. 2006
  5. doi request reprint Locally advanced and inflammatory breast cancer
    Stephen Chia
    Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, British Columbia, Canada
    J Clin Oncol 26:786-90. 2008
  6. ncbi request reprint The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer
    Stephen K Chia
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver and Victoria, British Columbia, Canada
    Cancer 110:973-9. 2007
  7. ncbi request reprint Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies
    Stephen K Chia
    Division of Medical Oncology, Breast Cancer Outcomes Unit, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, BC Canada, V5Z 4E6
    J Clin Oncol 22:1630-7. 2004
  8. doi request reprint Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers
    Stephen Chia
    Division of Medical Oncology, Breast Cancer Outcomes Unit, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 26:5697-704. 2008
  9. doi request reprint Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer
    Stephen Chia
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
    Clin Cancer Res 15:708-13. 2009
  10. doi request reprint A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
    Clin Breast Cancer 9:166-72. 2009

Detail Information

Publications39

  1. doi request reprint Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT
    Stephen Chia
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10 Avenue, Vancouver, BC, Canada
    J Clin Oncol 26:1664-70. 2008
    ..Because many patients subsequently experience progression or relapse, it is important to identify agents with efficacy after AI failure...
  2. doi request reprint Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer
    Stephen Chia
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada
    Breast 17:S16-21. 2008
    ....
  3. pmc A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen
    Stephen K Chia
    Department of Medical Oncology, British Columbia Cancer Agency, British Columbia, Canada
    Clin Cancer Res 18:4465-72. 2012
    ..12) to evaluate the prognostic and predictive significance of intrinsic subtypes identified by both the PAM50 gene set and by immunohistochemistry...
  4. ncbi request reprint Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial
    Stephen Chia
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada
    J Clin Oncol 24:2773-8. 2006
    ....
  5. doi request reprint Locally advanced and inflammatory breast cancer
    Stephen Chia
    Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, British Columbia, Canada
    J Clin Oncol 26:786-90. 2008
  6. ncbi request reprint The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer
    Stephen K Chia
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver and Victoria, British Columbia, Canada
    Cancer 110:973-9. 2007
    ..This study characterized the use and assessed the impact on survival of population-based access to new agents for the treatment of MBC...
  7. ncbi request reprint Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies
    Stephen K Chia
    Division of Medical Oncology, Breast Cancer Outcomes Unit, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, BC Canada, V5Z 4E6
    J Clin Oncol 22:1630-7. 2004
    ..We assessed the 10-year outcomes in a population-based cohort of node-negative (N-) lymphovascular negative (LV-) early breast cancers diagnosed from 1989 to 1991 who did not receive adjuvant systemic therapy...
  8. doi request reprint Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers
    Stephen Chia
    Division of Medical Oncology, Breast Cancer Outcomes Unit, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 26:5697-704. 2008
    ..This study assessed the prognostic impact of HER2 overexpression/amplification in a large series of node-negative breast cancers...
  9. doi request reprint Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer
    Stephen Chia
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
    Clin Cancer Res 15:708-13. 2009
    ..The primary objective of this phase II trial was to assess the safety and efficacy of the combination of OGX-011 and docetaxel for metastatic breast cancer...
  10. doi request reprint A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
    Clin Breast Cancer 9:166-72. 2009
    ....
  11. ncbi request reprint The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis
    Shahriar Dabiri
    Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Mod Pathol 17:690-5. 2004
    ....
  12. ncbi request reprint Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas
    Lindsay A Brown
    Genetic Pathology Evaluation Centre of the Prostate Centre, University of British Columbia, Room 509, JBRC, 2660 Oak St, Vancouver, BC, Canada V6H 3Z6
    Gynecol Oncol 100:264-70. 2006
    ..Here, we investigate the role of EMSY, a recently described BRCA2 interacting protein, as a key element of the 11q13 amplicon in ovarian cancer. EMSY maps to 11q13.5 and is amplified in 13% of breast and 17% of ovarian carcinomas...
  13. doi request reprint Micrometastatic node-positive breast cancer: long-term outcomes and identification of high-risk subsets in a large population-based series
    Pauline T Truong
    Breast Cancer Outcomes Unit, British Columbia Cancer Agency, Victoria, BC, Canada
    Ann Surg Oncol 17:2138-46. 2010
    ..2 mm but < or =2 mm (pNmic) is unclear. This study evaluates survival in pNmic relative to node-negative (N0) and macroscopic node-positive (pNmac) disease in a large population-based series...
  14. doi request reprint Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients
    Orit Freedman
    Division of Medical Oncology, Princess Margaret Hospital, Suite 5 205, 610 University Avenue, Toronto, ON, M5G 2M9, Canada
    Breast Cancer Res Treat 118:377-83. 2009
    ..70 (95% CI 0.60-0.80). This model was able to identify risk information that could be helpful in assessing which patients would most likely benefit from fulvestrant as an intervention with the objective being a delay in chemotherapy...
  15. ncbi request reprint A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130
    Karen A Gelmon
    British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada, V5Z 4E6
    Invest New Drugs 23:445-53. 2005
    ..This phase I trial was conducted to determine the maximum tolerated dose, recommended phase II dose, pharmacokinetic properties and toxicities of this agent...
  16. ncbi request reprint NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis
    Leah M Prentice
    Department of Pathology and Prostate Centre, Genetic Pathology Evaluation Centre, Vancouver General Hospital, Vancouver, BC, Canada V6H 3Z6
    Oncogene 24:7281-9. 2005
    ..Of the two genes in the novel amplicon, expression of SPFH2 correlated most significantly with amplification. This amplicon may emerge as a result of breakpoints and chromosomal rearrangements within the NRG1 locus...
  17. ncbi request reprint Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction
    Corinna Warburton
    Department of Advanced Therapeutics, British Columbia Cancer Agency, Vancouver, Canada
    Clin Cancer Res 10:2512-24. 2004
    ....
  18. doi request reprint Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study
    Richard Shaffer
    British Columbia Cancer Agency, Vancouver, Canada
    Radiother Oncol 90:122-6. 2009
    ..To examine the acute cardiotoxicity of internal mammary chain (IMC) irradiation with concurrent trastuzumab...
  19. doi request reprint Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors
    Yuanmei Lou
    Department of Integrative Oncology, BC Cancer Agency, British Columbia, Canada
    Cancer Res 71:3364-76. 2011
    ..Our findings show that CAIX is vital for growth and metastasis of hypoxic breast tumors and is a specific, targetable biomarker for breast cancer metastasis...
  20. pmc Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer
    Lindsay Hedden
    Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, V5Z 1L3 Canada
    Oncologist 17:164-71. 2012
    ..The objective of this study is to evaluate the cost-effectiveness of the currently recommended 12-month adjuvant protocol of trastuzumab using a Markov modeling approach and real-world cost data...
  21. doi request reprint Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163
    Susan L Ellard
    BC Cancer Agency Southern Interior, 399 Royal Ave, Kelowna, British Columbia, Canada V1Y 5L3
    J Clin Oncol 27:4536-41. 2009
    ....
  22. ncbi request reprint A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer
    Kim N Chi
    BC Cancer Agency, Vancouver, British Columbia, Canada
    Invest New Drugs 23:311-5. 2005
    ..Phase I trials of ONT-093 in normal human volunteers showed no dose-limiting toxicities at serum concentrations associated with biologic activity achieved with doses ranging from 300 to 500 mg...
  23. ncbi request reprint Population-based validation of the prognostic model ADJUVANT! for early breast cancer
    Ivo A Olivotto
    Breast Cancer Outcomes Unit, Vancouver Island Centre, 2410 Lee Avenue, Victoria, BC V8R 6V5, Canada
    J Clin Oncol 23:2716-25. 2005
    ..Adjuvant! (www.adjuvantonline.com) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated...
  24. doi request reprint Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen
    Hagen Kennecke
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer 112:1437-44. 2008
    ..An understanding of which patients are at risk of early recurrence while they are receiving tamoxifen may improve clinical decision making...
  25. doi request reprint Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients
    Shuzhen Liu
    Genetic Pathology Evaluation Centre at Vancouver General Hospital, Prostate Center, University of British Columbia, Vancouver, BC, Canada
    Breast Cancer Res Treat 119:53-61. 2010
    ..PR adds significant prognostic value in breast cancer beyond that obtained with estrogen receptor alone...
  26. pmc The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities
    Paulos Teckle
    Canadian Centre for Applied Research in Cancer Control ARCC, Vancouver, BC, Canada
    Health Qual Life Outcomes 9:106. 2011
    ..To evaluate the validity of cancer-specific and generic preference-based instruments to discriminate across different measures of cancer severities...
  27. ncbi request reprint Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer
    Ivo A Olivotto
    Breast Cancer Outcomes Unit, Victoria, British Columbia, Canada
    J Clin Oncol 21:851-4. 2003
    ....
  28. ncbi request reprint The development of a standardized software platform to support provincial population-based cancer outcomes units for multiple tumour sites: OaSIS - Outcomes and Surveillance Integration System
    Jonn Wu
    BC Cancer Agency, Vancouver, British Columbia
    Stud Health Technol Inform 183:98-103. 2013
    ..This will also facilitate initiatives to improve patient outcomes, decision support in achieving operational efficiencies and an environment that supports knowledge generation...
  29. doi request reprint Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?
    Ana Elisa Lohmann
    British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada
    Curr Treat Options Oncol 13:249-62. 2012
    ..In this article we will review the bevacizumab mechanism of action and the clinical trials that assessed its benefit in the treatment of metastatic breast cancer (MBC)...
  30. doi request reprint The clonal and mutational evolution spectrum of primary triple-negative breast cancers
    Sohrab P Shah
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada
    Nature 486:395-9. 2012
    ..Taken together, our results show that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes...
  31. doi request reprint Encapsulated apocrine papillary carcinoma of the breast--a tumour of uncertain malignant potential: report of five cases
    Melanie Seal
    The Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
    Virchows Arch 455:477-83. 2009
    ..All lacked evidence of malignancy in the breast tissue outside of the lesion. Sentinel lymph node biopsies performed in three of the cases were negative for metastases, and all have behaved in a benign fashion...
  32. ncbi request reprint A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma
    Nikita Makretsov
    Genetic Pathology Evaluation Centre of Department of Pathology and Prostate Centre, British Columbia Cancer Agency, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Genes Chromosomes Cancer 40:152-7. 2004
    ..In all cases, the results from the fusion and split-apart FISH assays for the ETV6-NTRK3 fusion genes were concordant. Our data suggest that the ETV6-NTRK3 fusion gene is a specific genetic alteration in SBC...
  33. pmc Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
    J Natl Cancer Inst 101:736-50. 2009
    ....
  34. doi request reprint Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer
    Simon J Crabb
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Breast Cancer 8:249-56. 2008
    ..We hypothesized that molecular classification based on breast cancer biology would predict the presence of nodal involvement at diagnosis, which might aid treatment decisions regarding the axilla...
  35. doi request reprint Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:1368-76. 2008
    ..This study directly compares the prognostic significance between three- and five-biomarker surrogate panels to define intrinsic breast cancer subtypes, using a large clinically annotated series of breast tumors...
  36. ncbi request reprint Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre at Vancouver General Hospital, Prostate Centre, and University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 24:5637-44. 2006
    ....
  37. pmc Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers
    Reka Pataky
    Cancer Control Research, BC Cancer Agency, 675 W, 10th Ave, Vancouver, BC V5Z 1L3, Canada
    BMC Cancer 13:339. 2013
    ..The purpose of this study was to calculate the cost-effectiveness of MRI screening for breast cancer in BRCA1/2 mutation carriers in a Canadian setting...
  38. doi request reprint What is the difference between triple-negative and basal breast cancers?
    Melanie D Seal
    Department of Medical Oncology, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada
    Cancer J 16:12-6. 2010
    ..Furthermore, even within the basal-like subtype, diversity exists. The purpose of this review is to outline the most current evidence in an attempt to answer the question: what is BLBC?..
  39. ncbi request reprint Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression
    Aruna Somasiri
    Department of Anatomy and Cell Biology, University of British Columbia, 2177 Wesbrook Mall, Vancouver, BC, Canada V6T 1Z3
    Cancer Res 64:5068-73. 2004
    ..Therefore, podocalyxin overexpression is a novel predictor of breast cancer progression that may contribute to the process by perturbing tumor cell adhesion...